- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
BioSante Pharmaceuticals (AMEX: BPA) today announced that Stephen M. Simes, its president and CEO will present a corporate overview and update at two upcoming conferences. The conferences are:
* The Think Equity Partners' ThinkClinic: An Educational Forum for Healthcare Investors Conference on October 4, 2007 at 9:40 a.m. local time at the Pierre Hotel in New York.
* The Bio Investor Forum on October 10, 2007 at 11:15 a.m. local time at the Palace Hotel in San Francisco.
A live audio webcast of BioSante's presentation at these conferences can be accessed on the internet by visiting http://www.biosantepharma.com . An archive of these presentations will be available at the same address.
These conferences each feature companies presenting to a diverse group of investors, portfolio managers and analysts interested in the biotechnology and pharmaceuticals sectors as well as biotech and pharmaceutical company representatives.
About BioSante Pharmaceuticals
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.7 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including avian flu and biodefense vaccines, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine.
For more information, please click here
BioSante Pharmaceuticals, Inc.
Copyright © Business Wire 2007If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016